Immunohistochemical evaluation of multiple biological markers in ductal carcinoma in situ of the breast

被引:31
|
作者
Perin, T
Canzonieri, V
Massarut, S
Bidoli, E
Rossi, C
Roncadin, M
Carbone, A
机构
[1] IST NAZL RICOVERO & CURA CARATTERE SCI, CTR RIFERIMENTO ONCOL AVIANO, DIV PATHOL, AVIANO, ITALY
[2] IST NAZL RICOVERO & CURA CARATTERE SCI, CTR RIFERIMENTO ONCOL AVIANO, DIV SURG ONCOL, AVIANO, ITALY
[3] IST NAZL RICOVERO & CURA CARATTERE SCI, CTR RIFERIMENTO ONCOL AVIANO, DIV EPIDEMIOL, AVIANO, ITALY
[4] IST NAZL RICOVERO & CURA CARATTERE SCI, CTR RIFERIMENTO ONCOL AVIANO, DIV RADIOTHERAPY, AVIANO, ITALY
关键词
c-erbB-2; p53; ER; PR; pS2; cath-D; CD44; MLuC5; ductal carcinoma in situ of the breast;
D O I
10.1016/0959-8049(96)00037-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In order to obtain prognostic clinicopathological information, 49 cases of pure ductal carcinoma in situ of the breast (DCIS), were evaluated for the immunohistochemical expression of potential predictor markers including c-erbB-2 oncogene product, p53 protein, oestrogen (ER) and progesterone (PR) receptors, oestrogen-regulated proteins pS2 and cathepsin-D (cath-D), CD44 protein and 67-kDa laminin receptor (MLuC5). Immunohistochemical findings were compared with conventional pathological parameters, clinical findings, and the clinical outcome of the patients. When markers were matched to each other, statistical analyses provided a significant positive correlation between c-erbB-2 overexpression and p53 positivity (P < 0.01) and between ER and PR (P < 0.01), ER, PR and pS2 (P < 0.01), pS2 and MLuC5 (P < 0.05). Significant negative correlations between c-erbB-2 overexpression and ER (P < 0.05), PR (P < 0.01) and pS2 (P < 0.01) positivity was also observed. Data on the relationship between marker status and pathological findings revealed a significant positive trend between c-erbB-2, p53, and increased grade values (P < 0.05) and opposite results with SR receptor expression (P < 0.01). c-erbB-2 overexpression was further significantly associated with comedotype carcinoma (P < 0.05) and distribution of disease in confluent neoplastic ducts (P < 0.01). Although no statistically significant correlation among biological markers expression, clinical findings and outcome was demonstrated, overall this study indicates that tumour cells from a subset of DCIS, which includes comedotype carcinoma, express significantly unfavourable prognostic factors. Copyright (C) 1996 Elsevier Science Ltd
引用
收藏
页码:1148 / 1155
页数:8
相关论文
共 50 条
  • [21] Histological and Immunohistochemical Evaluation of Ductal Carcinoma In Situ Co-Existing with Triple-Negative Carcinoma of the Breast
    Seol, Hyesil
    Ko, Hyoungsuk
    Park, In Ae
    KOREAN JOURNAL OF PATHOLOGY, 2008, 42 (06) : 373 - 380
  • [22] Immunohistochemical analysis of cancer stem cell markers in invasive breast carcinoma and associated ductal carcinoma in situ: relationships with markers of tumor hypoxia and microvascularity
    Currie, Margaret J.
    Beardsley, Brooke E.
    Harris, Gavin C.
    Gunningham, Sarah P.
    Dachs, Gabi U.
    Dijkstra, Birgit
    Morrin, Helen R.
    Wells, J. Elisabeth
    Robinson, Bridget A.
    HUMAN PATHOLOGY, 2013, 44 (03) : 402 - 411
  • [23] Tissue microarray immunohistochemical profiling of ductal carcinoma in situ of the breast.
    Meijnen, P
    Peterse, JL
    Rutgers, EJ
    Van de Vijver, MJ
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9063S - 9063S
  • [24] Immunohistochemical profile of high-grade ductal carcinoma in situ of the breast
    Perez, Amanda Arantes
    Rocha, Rafael Malagoli
    Balabram, Debora
    Souza, Atila da Silva
    Gobbi, Helenice
    CLINICS, 2013, 68 (05) : 674 - 678
  • [25] Clinicopathological features and biological markers predicting recurrence in ductal carcinoma in situ (DCIS) of the breast: A retrospective analysis
    Altintas, Sevilay
    Thirza Huizing, Manon
    Lambein, Kathleen
    Van Marck, Erik
    Hellemans, Hilde
    Weyler, Joost
    Praet, Marleen
    Baptist Vermorken, Jan
    Tjalma, Wiebren
    ANNALS OF ONCOLOGY, 2006, 17 : 104 - 104
  • [26] THE CLASSIFICATION OF DUCTAL CARCINOMA IN-SITU AND ITS ASSOCIATION WITH BIOLOGICAL MARKERS
    BOBROW, LG
    HAPPERFIELD, LC
    GREGORY, WM
    SPRINGALL, RD
    SEMINARS IN DIAGNOSTIC PATHOLOGY, 1994, 11 (03) : 199 - 207
  • [27] Immunohistochemical Expression of E-cadherin in Sclerosing Adenosis, Ductal Carcinoma In Situ and Invasive Ductal Carcinoma of the Breast
    Facina, Gil
    Lopes-Costa, Pedro Vitor
    Dos Santos, Alesse Ribeiro
    De Vasconcelos-Valenca, Rodrigo Jose
    Pinho-Sobral, Andre Luis
    Ferreira-Filho, Celso Fires
    Alencar, Airlane Pereira
    Gebrim, Luiz Henrique
    Da Silva, Benedito Borges
    DIAGNOSTIC CYTOPATHOLOGY, 2010, 38 (04) : 235 - 238
  • [28] Use of immunohistochemical markers to estimate degree of malignancy of infiltrating ductal breast carcinoma
    Astakhov, D.
    Kogan, E.
    Kovalenko, V.
    Schvets, S.
    ANNALS OF ONCOLOGY, 2008, 19 : 40 - 40
  • [29] Paxillin expression and EMT markers in breast ductal carcinoma in situ (DCIS)
    Logullo, F. A.
    Pasini, S. F.
    Nonogaki, S.
    Osorio, C.
    Soares, A. F.
    Brentani, M. M.
    VIRCHOWS ARCHIV, 2009, 455 : 92 - 93
  • [30] Molecular markers for predicting progression of pure ductal carcinoma in situ of the breast
    Abuazar, Carolina Sens
    Ferreira, Elisa Napolitano e
    de Toledo, Cynthia Aparecida Bueno
    Soares, Fernando Augusto
    Rocha, Rafael Malagoli
    Carraro, Dirce Maria
    CANCER RESEARCH, 2010, 70